Recent posts and comments

• Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News

  A number of New England’s life sciences companies had good news to report this week.

  —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) reported results from clinical trials that indicate its experimental... Read more »

• Spark, Bezos Back Aviary, American Well Nabs $10M, Virdante Banks $30M, & More Boston-Area-Deals News

  An unusually high percentage of this week’s New England tech and life sciences deals came from companies based in Boston proper. What’s up with that?

  —Spark Capital of Boston led... Read more »

• European Regulators Question Antigenics and Biogen Idec Drugs, BioAssets Bags $30M in Option Deal, & More Boston-Area Life Sciences News

  Europe’s drug regulators were not kind to a couple of Massachusetts biotech firms this week, but other New England life sciences companies had happier news to report.

  —European drug regulators turned... Read more »

• BioAssets Inks $30M Option Deal

  Frazer, PA-based Cephalon (NASDAQ: CEPH) has agreed to pay $30 million for an option to acquire BioAssets Development Corporation, a Wellesley, MA-based company investigating spinal uses for existing and experimental... Read more »

• HubSpot Spots $16M, Synageva BioPharma Secures $12M, Currensee Sews Up $6M, & More Boston-Area Deals News

  Lots of venture news this week, with more than the usual number of software and Web companies making appearances.

  —Flexion Therapeutics raised $33 million in a Series A round led... Read more »

• Flexion Pulls in $33M, Cubist Teams With Hydra, Charles River Makes Cuts, & More Boston-Area Life Sciences News

  There was a steady serenade of news from New England’s life sciences companies this past week, with both the startups and the public firms chiming in.

  —Ryan profiled Boston BioCom, a... Read more »

• Cisco Snags Starent for $2.9B, Rocket Software Raises $91.9M, & More Boston-Area Deals News

  Not much deals news to round up this week, thanks to the Monday holiday and the fact that last week’s roundup slipped to this week. But just in case you missed... Read more »

• Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News

  It’s been a short week and a long weekend since last I rounded up New England’s life sciences news, but there were still a few stories worth mentioning.

  —Luke took an... Read more »

• Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News

  It was a busy week in the land of New England life sciences. Let’s dive in.

  —Luke did a massive analysis of the financial health of all the public biotech companies... Read more »

• Google Backs Adimab, PVI Sweetens E Ink Deal, Sanofi-Aventis Partners With Merrimack Pharma, & More Boston-Area Deals News

  As has been the case in recent weeks, M&A news featured prominently in this week’s New England tech and life sciences deals.

  —Harvard spinoff Tetraphase Pharmaceuticals of Watertown, MA, raised $10... Read more »

• Xconomy Channels Startups and Life Sciences

  Notice anything new here? Over to the right a little… Little more… Next to the map? (Bear with me, loyal RSS and e-mail subscribers, this will all make sense in a... Read more »

• A123Systems Pulls Off Big IPO, PrimeraDx Grabs $20M, Conduit Labs Collects $3M, and More Boston-Area Deals News

  The big news this week was obviously the A123Systems IPO, but quite a few other New England tech and life sciences firms had deals to report as well.

  —Mansfield, MA-based PrimeraDx... Read more »

• Biogen Idec Still Pursuing Facet Acquisition, Helicos Gets $10M Reprieve, Seaside Collects $30M for Autism Drug Development, & More Boston-Area Life Sciences News

  New England’s diagnostics developers provided more than their fair share of life sciences news this week.

  —Rick Jones, CEO of Cambridge, MA-based Ascent Therapeutics, talked with Ryan about his... Read more »

• Biogen Tender Offer For Facet Begins

  The Cambridge, MA-based Biogen Idec (NASDAQ: BIIB) today began a $14.50-per-share tender offer for Redwood City, CA-based Facet Biotech (NASDAQ: FACT). Biogen initially proposed to acquire the California company... Read more »

• A123 Plans $200M+ IPO, Seaside Sees $30M, Verivue Grabs $20.1M, & More Boston-Area Deals News

  New England’s tech and life sciences companies have cut far too many deals to mention over the last week and a half, so we’re kicking it top-ten style for this installment... Read more »

• Acceleron Aims for Anemia Cure, Mascoma to Pump Out Biofuels For Chevron, Genzyme Chief to Head Boston Fed, & More Boston-Area Life Sciences News

  This week saw the demise of a couple of New England life sciences firms and the rise of several others.

  —Luke profiled the efforts of Cambridge, MA-based Acceleron Pharma to bring... Read more »

• Highland Leads $9M InXpo Deal

  Highland Capital Partners of Boston led a $9 million first round of financing for InXpo, the Chicago-based startup announced. Founded in 2004, InXpo creates virtual events and virtual business environments... Read more »

• Federal Judge Rules in Biogen Idec’s Favor, Sepracor Agrees to $2.8B Buyout, FDA Panel Endorses Gloucester Pharma Drug, & More Boston-Area Life Sciences News

  The buyout of Sepracor was probably the biggest piece of New England life sciences news this past week, but it certainly wasn’t the only one.

  —Cambridge, MA-based Quanterix named David Okrongly... Read more »

• Calling All WordPress/PHP/Apache/Linux Gurus—Particularly the Ones With Pagers

  As we’ve grown Xconomy.com over the last few years, we’ve prided ourselves on keeping our operations lean and mean, in no small part by making the most of DIY technologies and... Read more »

• Sepracor Snatched up for $2.6B, EMC Acquires FastScale and Kazeon, Biogen Makes Bid For Facet, & More Boston-Area Deals News

  The pace of New England tech and life sciences deal making was swift over the last week and a half—and there was noticeable bump in M&A transactions.

  —Boston-based RockPort Capital Partners ... Read more »